Study Findings on Breast Cancer Are Outlined in Reports from Qiqihar Medical University (Meta-analysis and Network Pharmacology-based Investigation of Shenqi Fuzheng Injection Plus Docetaxel for the Efficacy and Molecular Mechanism of Breast...).

A recent study conducted by researchers at Qiqihar Medical University in China explored the potential benefits of combining Shenqi Fuzheng Injection (SFI), a Chinese medicine immunomodulator, with docetaxel (DOC) for the treatment of breast cancer (BC). The study involved a meta-analysis of 11 studies and found that SFI plus DOC was associated with increased objective response rate, improved immune capacity, decreased tumor marker levels, and reduced incidence of adverse reactions compared to DOC alone. Network pharmacology and molecular docking analyses revealed potential mechanisms of action involving specific active ingredients and target genes. However, further pharmacological experiments are needed to validate these findings. [Extracted from the article]